X4 Pharmaceuticals (NASDAQ:XFOR) Announces Earnings Results, Beats Estimates By $0.04 EPS

X4 Pharmaceuticals (NASDAQ:XFOR) posted its earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04, FiscalAI reports. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. The business had revenue of $2.71 million for the quarter, compared to analyst estimates of $3.20 million.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR traded up $0.19 during midday trading on Wednesday, hitting $4.39. The company had a trading volume of 500,104 shares, compared to its average volume of 453,509. The company has a quick ratio of 9.98, a current ratio of 10.16 and a debt-to-equity ratio of 0.41. The stock has a market cap of $398.68 million, a price-to-earnings ratio of -1.01 and a beta of 0.31. The firm has a fifty day simple moving average of $3.99 and a two-hundred day simple moving average of $3.80. X4 Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $4.83.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on XFOR shares. Guggenheim assumed coverage on shares of X4 Pharmaceuticals in a research note on Monday, March 9th. They issued a “buy” rating and a $12.00 target price on the stock. Weiss Ratings upgraded shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Finally, Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.50.

Institutional Trading of X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of XFOR. Rhumbline Advisers grew its position in X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after purchasing an additional 9,690 shares during the last quarter. Two Sigma Investments LP bought a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth about $47,000. Squarepoint Ops LLC bought a new position in shares of X4 Pharmaceuticals during the 4th quarter worth about $50,000. Stifel Financial Corp bought a new position in shares of X4 Pharmaceuticals during the 4th quarter worth about $82,000. Finally, Virtu Financial LLC bought a new position in shares of X4 Pharmaceuticals during the 4th quarter worth about $90,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.